realize the potential of Metabolic Medicine
KGK Synergize
Independent Lab Tests on
Cell Lines
Oncology Outcome Studies
Board Certified Oncologist 1,000 Patient/Stage IV Study
Published Articles
Poly-MVA / Lipoic Acid Complex articles on Pubmed.com
Poly MVA Inventor Papers
Dr. Merrill Garnett
Poly-MVA Research, Science and Studies
Poly MVA Laboratory
Lung Cancer Study
Low Dose Chemo Report
Stage 4 Oncology Studies
Frank Antonowich PhD
READ REPORT
Published Scientific Study
READ REPORT
Oncology Study Overview
READ REPORT
James W. Forysythe, M.D. H.M.D.
READ REPORT
Poly-MVA Articles
Cancer Tutor
Naturopathic Medicine
Cancer-Stroke-Anti-Aging
Cancer-Stroke-Anti-Aging
In 2007, KGK Science, Inc., an independent laboratory in Canada, examined the effects of POLY-MVA on 8 cancer cell lines.
These lines included:
1) Skin melanoma, human (SKMel-5)
2) Liver, hepatocellular carcinoma, human (Hep G2)
3) Lung, malignant melanoma, human (Malme-3M)
4) Mammary gland, ductal carcinoma, human (MDA-MB 435)
5) Prostate, left supraclavicular lymph node carcinoma, human (LNCaP)
6) Colon, colorectal adenocarcinoma, human (HT-29)
7) Human brain, glioblastoma; astrocytoma (U87)
8) Glioblastoma (HT-80)
POLY-MVA was administered at 3 different dosages and the number of cells was examined after 24, 48 and 72 hours following initial application. POLY-MVA was effective, to varying degrees, on the entire group of cell lines tested (melanoma, liver, lung, breast, prostate, colon, astrocytoma and glioblastoma).
The varying effectiveness appears to be a consequence of the particular cell lines used and their associated degree of anaplasia.
The graph above demonstrates the benefit of POLY-MVA after 48 hours of initial exposure: The Y-axis represents the number of cells per mL.
Poly MVA causes significant cell death after 48 Hours of exposure
per mL. SHAPE \* MERGEFORMAT CPM
The table below illustrates the statistically significant level of cell death
(p must be equal to or less than 0.05) induced by POLY-MVA after 48 hours of initial exposure:
Garnett McKeen In vitro Cancer Assays:
Garnett McKeen Laboratory Inc. (GML) chose to mimic the National Cancer Institute’s (NCI) cell screening protocol.
The following cell lines were selected from the NCI repository:
MCF-7 (breast adenocarcinoma), and A549 (lung non-small cell adenocarcinoma).
The data below represents the completion of the Breast Cancer (MCF-7), Ovarian Cancer (OVCAR-5) and Lung Carcinoma (A549) assay.
We have also completed assays using stage IV glioblastoma multiforme (H-80) and astrocytoma (H-4) brain tumor lines.
As noted below, all of the studies demonstrated significant cell death.
CANCER CELL DEATH RATE IN 5 CELL LINES
After 48 hours of exposure
